For decades, companion diagnosticsLoading... have relied on expression-based biomarkers–measuring how much of a target protein is present. PD-L1 IHC exemplifies this approach: tumor proportion score reports the percentage of cells expressing PD-L1.
Yet clinical data consistently reveal the limitation: in NSCLC, only ~41% of 'high PD-L1' patients respond to pembrolizumab. The 59% who don't respond met the expression criterion but lacked functional checkpoint engagement.
Functional biomarkers address this gap by measuring molecular activity–receptor-ligand binding, kinase activation, pathway engagement. The question shifts from "is it there?" to "is it working?"